Belgium urges unified EU response to US generic drug tariffs

Belgian Foreign Minister Maxime Prevot has urged European Union members to respond collectively to planned US tariffs on imported generic medicines, warning that fragmented national approaches would undermine the continent's ability to secure affordable supplies. Posting on social media platform X, Prevot stated that "Europe needs to respond to this challenge as one, defending both innovation and an open, secure supply, in everyone's interest," noting that pharmaceutical production chains are global and deeply interconnected.

He warned that raising trade barriers could increase costs and jeopardize the security of medicine supplies for patients in Europe and elsewhere. The intervention comes amid growing concern in Brussels over Washington's protectionist trade agenda targeting the pharmaceutical sector.

Trump announces 100% tariff

US President Donald Trump announced that a 100% tariff would be applied to imported generic drug products starting in August 2028, a move that threatens to disrupt global medicine markets. The decision provides a four-year implementation window, though observers noted the timeline offers limited relief for an industry dependent on just-in-time production networks.

Washington has framed the measure as necessary to reshore pharmaceutical manufacturing, but European officials counter that abrupt tariff walls would sever supply chains refined over decades of transatlantic cooperation.

Impact on Belgian exports

The tariff plan carries particular significance for Belgium, where the pharmaceutical sector accounts for more than half of the country's total exports to the United States. Industry analysts said the 100% levy would effectively price Belgian generic medicines out of the American market unless European negotiators secure exemptions before the 2028 deadline.

Belgian trade statistics show the country's pharmaceutical industry has long served as a primary supplier of generic drugs to the US market, with facilities in Flanders and Wallonia feeding distribution networks across North America. Prevot emphasized that defending open supply lines remains in the interest of both European and American patients.